- Home
- ACAD vs MATX Comparison
ACAD vs MATX Comparison
Compare ACAD & MATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- MATX
- Stock Information
- Founded
- ACAD 1993
- MATX 1882
- Country
- ACAD United States
- MATX United States
- Employees
- ACAD N/A
- MATX N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- MATX Marine Transportation
- Sector
- ACAD Health Care
- MATX Consumer Discretionary
- Exchange
- ACAD Nasdaq
- MATX Nasdaq
- Market Cap
- ACAD 3.8B
- MATX 3.6B
- IPO Year
- ACAD 2004
- MATX N/A
- Fundamental
- Price
- ACAD $20.98
- MATX $116.23
- Analyst Decision
- ACAD Buy
- MATX Buy
- Analyst Count
- ACAD 18
- MATX 5
- Target Price
- ACAD $27.71
- MATX $143.75
- AVG Volume (30 Days)
- ACAD 2.0M
- MATX 343.7K
- Earning Date
- ACAD 08-05-2025
- MATX 07-31-2025
- Dividend Yield
- ACAD N/A
- MATX 1.17%
- EPS Growth
- ACAD N/A
- MATX 78.79
- EPS
- ACAD 1.37
- MATX 15.15
- Revenue
- ACAD $996,283,000.00
- MATX $3,481,700,000.00
- Revenue This Year
- ACAD $13.39
- MATX N/A
- Revenue Next Year
- ACAD $10.59
- MATX $3.34
- P/E Ratio
- ACAD $15.33
- MATX $7.68
- Revenue Growth
- ACAD 22.42
- MATX 11.88
- 52 Week Low
- ACAD $13.40
- MATX $91.75
- 52 Week High
- ACAD $25.23
- MATX $169.12
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- MATX 58.86
- Support Level
- ACAD $20.75
- MATX $110.20
- Resistance Level
- ACAD $23.09
- MATX $115.51
- Average True Range (ATR)
- ACAD 0.78
- MATX 3.12
- MACD
- ACAD -0.20
- MATX 0.34
- Stochastic Oscillator
- ACAD 9.83
- MATX 95.84
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The business segments of the company are Ocean Transportation which provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific, and Logistics segment which offers long haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.